NasdaqCM:CODX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Co-Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CODX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.1%

CODX

0.2%

US Medical Equipment

0.4%

US Market


1 Year Return

1,385.7%

CODX

24.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: CODX exceeded the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: CODX exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

CODXIndustryMarket
7 Day3.1%0.2%0.4%
30 Day-2.1%7.4%6.1%
90 Day-34.9%7.6%8.9%
1 Year1,385.7%1,385.7%25.9%24.8%20.5%17.8%
3 Year146.3%146.3%75.8%71.2%42.3%32.9%
5 Yearn/a143.9%124.8%84.2%63.4%

Price Volatility Vs. Market

How volatile is Co-Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Co-Diagnostics undervalued compared to its fair value and its price relative to the market?

38.69x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CODX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CODX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CODX is good value based on its PE Ratio (34.3x) compared to the US Medical Equipment industry average (53.4x).

PE vs Market: CODX is poor value based on its PE Ratio (34.3x) compared to the US market (19.1x).


Price to Earnings Growth Ratio

PEG Ratio: CODX is poor value based on its PEG Ratio (1.5x)


Price to Book Ratio

PB vs Industry: CODX is overvalued based on its PB Ratio (10.5x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Co-Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

23.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CODX's forecast earnings growth (23.6% per year) is above the savings rate (2.2%).

Earnings vs Market: CODX's earnings (23.6% per year) are forecast to grow faster than the US market (22.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CODX's revenue (24% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: CODX's revenue (24% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CODX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Co-Diagnostics performed over the past 5 years?

-2.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CODX has a high level of non-cash earnings.

Growing Profit Margin: CODX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CODX has become profitable over the past 5 years, growing earnings by -2% per year.

Accelerating Growth: CODX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CODX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.9%).


Return on Equity

High ROE: CODX's Return on Equity (24.2%) is considered high.


Next Steps

Financial Health

How is Co-Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: CODX's short term assets ($34.5M) exceed its short term liabilities ($3.0M).

Long Term Liabilities: CODX's short term assets ($34.5M) exceed its long term liabilities ($80.0K).


Debt to Equity History and Analysis

Debt Level: CODX is debt free.

Reducing Debt: CODX currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: CODX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CODX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Co-Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CODX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CODX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CODX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CODX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CODX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average board tenure


CEO

Dwight Egan (67 yo)

no data

Tenure

US$460,000

Compensation

Mr. Dwight H. Egan serves as the Chairman, Chief Executive Officer and President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan serves as President, Chief Executive Officer an ...


CEO Compensation Analysis

Compensation vs Market: Dwight's total compensation ($USD460.00K) is below average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: Dwight's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Dwight Egan
Chairmanno dataUS$460.00kno data
Richard Serbin
Independent Director3.42yrsUS$72.75k0%
$ 0
James Nelson
Independent Director1.17yrsUS$45.83k0.088%
$ 351.0k
Eugene Durenard
Independent Director1.33yrsUS$45.25k0%
$ 0
Edward Murphy
Independent Director1.33yrsUS$29.75k0.088%
$ 351.0k

1.3yrs

Average Tenure

67yo

Average Age

Experienced Board: CODX's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 65.1%.


Top Shareholders

Company Information

Co-Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Co-Diagnostics, Inc.
  • Ticker: CODX
  • Exchange: NasdaqCM
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$396.900m
  • Shares outstanding: 28.27m
  • Website: https://www.codiagnostics.com

Number of Employees


Location

  • Co-Diagnostics, Inc.
  • 2401 South Foothill Drive
  • Suite D
  • Salt Lake City
  • Utah
  • 84109
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CODXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2017
C97MUN (Boerse Muenchen)YesCommon StockDEEURJul 2017
C97DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2017

Biography

Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 23:41
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.